Latest Articles
-
Pfizer Spending Twice As Much On Selling Than Research?
Pfizer (NYSE:PFE) spends nearly twice the money on selling, general & administrative (SG&A) expenses than it does on research & development (R&D). SG&A Accounted for 34% of the company’s total expenditure in 2018, whil...
-
Why Arrowhead Pharma Stock Has Rallied 30% Over The Last Month
Arrowhead Pharmaceuticals (NASDAQ: ARWR), a company that focuses on the treatment of intractable diseases by targeting the genes that cause them, has seen its stock rise by over 30% over the last month. The company currently has a pipeline of 9 d...
-
Pfizer’s Xeljanz In the Crowded Rheumatoid Drugs Market
Pfizer’s (NYSE:PFE) Rheumatoid Arthritis drug ~ Xeljanz ~ is a relatively small drug with sales of around $2 billion, and it accounts for around 4% of the total rheumatoid arthritis drugs market. AbbVie’s Humira is the leader based ...
-
Why Ultragenyx Pharmaceutical Stock Has Dropped 40% In The Last Quarter
Ultragenyx Pharmaceuticals (NASDAQ: RARE), a biopharmaceutical company focused on serious rare and ultra-rare genetic diseases, has seen its stock price decline by close to 40% over the last 3 months. The decline could be due to the fact that the...
-
Pfizer’s Lyrica In the Anti-Epileptic Drugs Market
Pfizer ‘s (NYSE:PFE) Lyrica is the leader in the anti-epileptic drugs market. Epilepsy is a condition in which a person has recurrent seizures. Other approved anti-epileptic drugs include UCB’s Keppra and Vimpat, GSK’s Lamictal...
-
Pfizer’s Prevnar vs Merck’s Pneumovax — Which Company Gets A Bigger Shot In the Arm?
Pfizer (NYSE:PFE) and Merck (NYSE:MRK) both participate in the pneumonia vaccination market, and both cater to different age groups. Pneumonia refers to lung inflammation caused by bacterial or viral infection. Pfizer’s Prevnar is the le...
-
Can Biosimilars Be The Next Growth Driver For Pfizer?
Biosimilars are versions of biologic medicines that have been developed and proven to be highly similar to the original biologic. They usually offer high-quality, lower-cost alternatives to biologic medicines. Pfizer (NYSE:PFE) has been focuse...
-
How Big Is Pfizer’s Generic Drugs Business That It Plans To Merge With Mylan?
Pfizer (NYSE:PFE) today announced its plan to combine its generic drugs business with Mylan in a Reverse Morris Trust transaction. The combined entity could generate sales of over $20 billion by 2020, and Pfizer will hold a 57% stake in the new ...
-
Pfizer Beats In Q1 But Lyrica Headwinds Will Likely Weigh On Near Term Growth
Pfizer (NYSE:PFE) recently reported its Q1 2019 results, which were above our estimates. This note details the company’s Q1 performance, and Trefis’ forecast for the full year 2019. You can view our interactive dashboard analysis ~ How Did Pfiz...
-
What To Expect From Pfizer’s Q1?
Pfizer (NYSE:PFE) is expected to publish its Q1 2019 results on April 30. This note details Trefis’ forecasts for Pfizer, as well as some of the key trends we will be watching when the company reports earnings. You can view our interactive dashb...
-
How Important Is Oncology For Pfizer?
Pfizer’s (NYSE:PFE) oncology business contributes more than 10% to its overall top line. This can be attributed to its breast cancer drug ~ Ibrance ~ which has been doing well of late, and it has a large addressable market. The contributio...
-
Pfizer’s Q4 Earnings And What Lies Ahead For The Company In 2019
Pfizer (NYSE:PFE) recently posted its Q4 results, which were slightly above the street estimates. The company’s overall sales grew 5%, while adjusted earnings per share was up 3%. As expected, the company saw higher sales for Ibrance, Eliquis, a...
-
Ibrance, Eliquis And Biosimilars Remain The Key Driver For Pfizer’s Future Earnings Growth
Pfizer (NYSE:PFE) recently posted its Q3 results, which were in line with our estimates. The company’s overall sales grew 2% while adjusted earnings per share grew 16%. As expected, the company saw higher sales for Ibrance, Eliquis, and Xeljanz,...
-
What To Expect From Pfizer’s Q3
Pfizer (NYSE:PFE) is set to report its Q3 2018 earnings on October 30, and we expect the company to post steady top line growth, primarily led by a ramp up in Ibrance sales, along with Eliquis, which has seen market share gains in the recent qua...
-
A Look At Pfizer’s Business And Outlook
Pfizer (NYSE:PFE) generates its revenues from its Oncology, Cardiovascular, Anti-Infective, Alimentary & Metabolism, Neuroscience, Immunology drugs, along with its Legacy Pharma, Consumer, Biosimilar & Other segment. Legacy Pharma, Cons...
